Caleb Youngblood, PA
Medical · Berkley, MINPI 1235366014
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,783 of the $215,491 with a category attached, or 64.4%. Gilead accounts for 67.2% of it on its own, with 47 other manufacturers making up the rest. 2025 is the largest year on record at $78,806, 3.0 times the $26,449 reported in 2021. Among medical clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,399 payments — averaging $154.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$145K
- Viiv Healthcare Company$55K
- Theratechnologies Inc.$3K
- Merck$2K
- Johnson & Johnson$1K
- Janssen Scientific Affairs, LLC$1K
- plus $7K from 42 others
What the payments were for
- Consulting fees$12,2906%
- Speaking & faculty fees$138,78364%
- Travel & lodging$36,79717%
- Food & beverage$27,36413%
- Education$2580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$215,491 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 272 | $1,069,714 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 60 | $334,161 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 67 | $233,911 |
| DescovyEmtricitabine/Tenofov Alafenam | 100 | $218,014 |
| DovatoDolutegravir Sodium/Lamivudine | 66 | $208,056 |
| PifeltroDoravirine | 83 | $162,568 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 33 | $142,351 |
| JardianceEmpagliflozin | 86 | $119,604 |
| TivicayDolutegravir Sodium | 35 | $88,416 |
| JulucaDolutegravir/Rilpivirine | 19 | $70,655 |
| PrezcobixDarunavir/Cobicistat | 23 | $55,964 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 14 | $51,416 |
| OzempicSemaglutide | 47 | $48,283 |
| EliquisApixaban | 32 | $45,250 |
| JanuviaSitagliptin Phosphate | 26 | $38,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $144,777 | $1,430,079405 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Juluca, Triumeq | $55,342 | $418,542134 claims |
| Janssen Products, LPSymtuza | $1,055 | $334,16160 claims |
| MerckPifeltro, Januvia, Delstrigo | $2,459 | $229,796121 claims |
| Boehringer IngelheimJardiance | $126 | $119,60486 claims |
| Johnson & JohnsonPrezcobix | $1,224 | $55,96423 claims |
| Novo NordiskOzempic | $589 | $48,28347 claims |
| PfizerEliquis | $409 | $45,25032 claims |
| AstraZenecaFarxiga | $444 | $33,58032 claims |
| Lilly USA, LLCTrulicity | $361 | $30,26319 claims |
| GSKTrelegy Ellipta | $90 | $18,42318 claims |
| AbbVieLinzess | $935 | $7,25414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.
Other medical in Berkley
- Mark RosenBerkley$32K
- Mayuri BharathanBerkley$8K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.